Genentech has announced that the U.S. Food and Drug Administration (FDA) has approved Tecentriq and Tecentriq Hybreza for the adjuvant treatment of adults with muscle-invasive bladder cancer (MIBC) who show circulating tumor DNA molecular residual disease (ctDNA MRD) after bladder removal surgery. The approval marks the first FDA-cleared ctDNA-guided therapy approach for this aggressive cancer type.
The newly approved approach uses a personalized MRD test, Signatera CDx, developed by Natera, to identify patients at higher risk of cancer recurrence after cystectomy. Physicians can now use serial ctDNA testing to determine which patients may benefit from immunotherapy while potentially sparing others from unnecessary treatment-related side effects.
The FDA decision was supported by results from the Phase III IMvigor011 clinical trial. According to Genentech, treatment with Tecentriq reduced the risk of disease recurrence or death by 36% and lowered the risk of death by 41% in ctDNA-positive patients compared with placebo. Researchers described the study as the first prospective Phase III trial to demonstrate survival benefit using a ctDNA-guided adjuvant treatment strategy in muscle-invasive bladder cancer.
Levi Garraway, Chief Medical Officer and Head of Global Product Development at Genentech, said the approval highlights the growing role of precision medicine in oncology care. Patient advocacy groups also welcomed the decision, noting that ctDNA-guided monitoring could help doctors intervene earlier in patients at high risk of relapse.
Muscle-invasive bladder cancer remains a major clinical challenge worldwide. Despite surgery, nearly half of patients experience disease recurrence. Experts believe this approval could reshape post-surgical cancer management by enabling more personalized treatment decisions based on molecular evidence rather than relying solely on tumor staging.
